NYSE · HEP
Energy · Oil & Gas Midstream
$20.45
Down-$0.16 (-0.78%)
Updated Aug 14, 2026, 1:10 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
HEP does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning HEP.
HEP research
Company profile and research snapshot.
Holly Energy Partners, L.P. provides petroleum product and crude oil transportation, terminalling, storage, and throughput services to the petroleum industry in the United States. It operates through two segments, Pipelines and Terminals, and Refinery Processing Unit. The company operates refined product pipelines that transport conventional gasolines, reformulated gasolines, and low-octane gasolines for oxygenate blending, as well as sulfur diesel and jet fuels, and liquefied petroleum gases; intermediate product pipelines that transport intermediate feedstocks and crude oils; and oil trunk, gathering, and connection pipelines that delivers crude oil. It operates 26 main pipelines; crude gathering networks; 10 refined product terminals; 1 crude terminal; 1 lube terminal; 31,800 track feet of rail storage; 7 locations with truck and/or rail racks; and tankages at 6 refining facility locations, as well as five refinery processing units. The company was incorporated in 2004 and is based in Dallas, Texas.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2023 | Raymond James | Market Perform | — |
| Aug 17, 2023 | Citigroup | Neutral | — |
| Aug 4, 2023 | Raymond James | Outperform | — |
| Jul 12, 2023 | Citigroup | Neutral | — |
| May 9, 2023 | Citigroup | Neutral | — |
No generated briefing is available yet.
globenewswire.com · Dec 11, 2025
Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists
prnewswire.com · Dec 8, 2025
Late Breaking Abstract titled "Targeting SCD1 enhances activity of standard of care regorafenib in hepatocellular carcinoma: translational rationale for a phase 1/2 study of the combination of Aramchol and regorafenib" to be presented with a poster on December 9 at 3pm (HST). RAMAT-GAN, Israel , Dec. 8, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HEP.
No results
No recent SID articles mention HEP.
